STOCK TITAN

Alkermes to Participate in the Stifel 2022 CNS Days

(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Tags
conferences

Rhea-AI Summary

Alkermes plc (Nasdaq: ALKS) announced that CEO Richard Pops will participate in a fireside chat at the Stifel 2022 CNS Days on March 29, 2022, at 8:30 a.m. ET. The event will be accessible via a live webcast on the company's website, with an archive available for 14 days afterward. Alkermes is a global biopharmaceutical company based in Dublin, focusing on innovative treatments in neuroscience and oncology, including products for alcohol dependence, opioid dependence, schizophrenia, and bipolar disorder.

Loading...
Loading translation...
Argus Session date unavailable
-0.04% session move Open Argus
Details

News Market Reaction – ALKS

The recorded move for ALKS in the trading session of this news was -0.04%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

DUBLIN, March 22, 2022 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that its Chief Executive Officer, Richard Pops, will participate in a fireside chat at the Stifel 2022 CNS Days on Tuesday, March 29, 2022 at 8:30 a.m. ET (1:30 p.m. BST). The live webcast may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days.

About Alkermes plc
Alkermes plc is a fully-integrated, global biopharmaceutical company developing innovative medicines in the fields of neuroscience and oncology. The company has a portfolio of proprietary commercial products focused on alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurodegenerative disorders and cancer. Headquartered in Dublin, Ireland, Alkermes has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. For more information, please visit Alkermes' website at www.alkermes.com.

Contact:
Alex Braun
Investor Relations
+1 781 296 8493

Alkermes plc Logo (PRNewsfoto/Alkermes plc)

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/alkermes-to-participate-in-the-stifel-2022-cns-days-301507471.html

SOURCE Alkermes plc

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When is Alkermes participating in the Stifel 2022 CNS Days?

Alkermes will participate in the Stifel 2022 CNS Days on March 29, 2022, at 8:30 a.m. ET.

Who is representing Alkermes at the Stifel 2022 CNS Days?

CEO Richard Pops will represent Alkermes at the Stifel 2022 CNS Days.

How can I access the Alkermes presentation at Stifel 2022 CNS Days?

The presentation can be accessed via a live webcast on Alkermes' website under the Investors tab.

What is the focus of Alkermes plc?

Alkermes focuses on developing innovative medicines in neuroscience and oncology, including treatments for alcohol and opioid dependence.

How long will the Alkermes webcast be available after the event?

The Alkermes webcast will be archived and available for 14 days after the event.

Keep reading